Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 57 for “"RAS mutations"”.
-
Customisation of therapeutic strategy in metastatic colorectal cancer by use of liquid biopsies (detection of RAS mutations with digital PCR)
… cancer and is associated with high mortality. RAS status is an important biomarker, as it guides treatment by predicting response to anti-EGFR monoclonal antibodies. However, RAS is routinely tested only on archival tumour tissue, and it is not possible to update the information on its status …
-
PHARMACOLOGIC RESTORATION OF GTP HYDROLYSIS SENSITIZES CELLS TO SHP2 INHIBITION IN RAS-MUTANT FUSION-NEGATIVE RHABDOMYOSARCOMA
… (FN-RMS), is often driven by hyperactive RAS signaling. Direct RAS inhibitors have yet to be evaluated in pediatric malignancies. Alternative targets to inhibit hyperactive RAS signaling include SHP2. SHP2 promotes RAS-SOS1 interaction, leading to GDP/GTP exchange and RAS activation. …
-
Impact of Kras/Nras Mutational Heterogeneity On Clinical Outcomes In Colorectal Cancer
Introduction: Mutations in KRAS/NRAS (RAS) predict a lack of benefit from anti-EGFR agents in metastatic colorectal cancer (mCRC). As next generation sequencing (NGS) has advanced, we are discovering atypical and low allele frequency mutations. We aimed to evaluate how NGS can optimally define RAS …
-
Μελέτη του ογκογονιδίου RAS και της μεταλλαγμένης μορφής του ογκοκατασταλτικού ογκογονιδίου P53 σε πλακώδη καρκινώματα πνεύμονα
… DNA repair and initiation of apoptosis. P53 mutations are detected in more than 50% of human tumours. Ras oncogene is also important for carcinogenesis, as its GTPase functioning protein product is critical for signal transduction. Ras mutations are frequently detected in human tumours …
-
Elucidating the Mechanisms Underlying the Mutational Bias of RAS Genes in Cancer Using a Chemical Carcinogenesis Mouse Model
<p>Missense oncogenic mutations in the RAS genes are found in around 20% of all human cancers, which are known to be tumorigenic. Despite scores of different oncogenic RAS mutations detected in human cancers, these mutations have distinct patterns, often with a specific set of mutations unique to …
-
Ανίχνευση του μεταλλαγμένου γονιδίου KRAS σε κυκλοφορούν ελεύθερο DNA πλάσματος και του μεταγράφου του σε αιμοπετάλια ασθενών με καρκίνο του παχέος εντέρου και μελέτη της κλινικής τους χρησιμότητας στην παρακολούθηση της νόσου
… NGS technique aiming at the identification of mutations in 23 genes. At the same time NGS was also applied in circulating tumor DNA isolated from patient’s plasma aiming at identification of possible mutations in a broad gene panel and furthermore investigation of KRAS mutations using digital …
-
Έκφραση του αναστολέα p27 στον μη-μικροκυτταρικό καρκίνο του πνεύμονα. Συσχέτιση με τους ρυθμιστές του κυτταρικού κύκλου p53 και pRb και τις κινητικές παραμέτρους
… of p27 levels with the presence of Ki-ras mutations, as well as with the expression status of p53 and pRb in tumor cells. Material and Methods: p27, p53 and pRb status were immunohistochemically evaluated in a total of 69 NSCLCs. In situ assays were employed to assess the kinetic …
-
blmp-1 is a Ras-cooperating Tumor Suppressor Gene in Caenorhabditis elegans
While hypermorphic Ras mutations are found in approximately 35% of colorectal, 45% of lung and 90% of pancreatic cancers, activated Ras alone is not sufficient to transform normal cells into cancerous tumors. Additional driver mutations or epigenetic alterations are required to cooperate with the …
-
Prognostic molecular markers in resected ductal pancreatic carcinoma
… DNA obtained from microdissected specimens. Mutations in codons 12 and 13 of the K-ras oncogene were detected by SSCP and sequencing following DNA extraction and amplification by PCR. The median [range] survival post-resection was 12.5 [3-83] months. Abnormalities of p16\(^{INK4}\), p53, …
-
Gene mutations in experimental models of carcinogenesis and their effects on responses to chemopreventive agents in the azoxymethane-treated rat model
The Ki-ras oncogene and the p53 tumor suppressor gene are mutated in a high percentage of human colon cancers. The mutation status of these two genes were assessed in colon adenocarcinomas obtained from azoxymethane (AOM)- and dimethylhydrazine (DMH)-treated rats, widely used experimental models of …
-
Interaction of beta-adrenergic receptors, NNK, and ethanol in selected pancreatic carcinoma cell lines
… Tobacco and alcohol are risk factors. Ki-ras and p53 commonly occur in genetic mutations, 75% and 50% respectively. However, the interconnection between these risk factors and genetic mutations and their role in pancreatic carcinogenesis has not been consistent. It has been …
-
Genomic Characterization of Response and Resistance to Immunotherapy in Black Patients with Non-Small Cell Lung Cancer
… sequencing (NGS) data encompassing 607,863 mutations in 66,372 tumors across 51 cancer types obtained from the AACR Project GENIE Registry to better understand the genomic landscape of cancers harboring RAS mutations stratified by racial background. These analyses revealed a differential …
-
Genetic Aberrations Associated With Metastasis in Colorectal Cancer: An Insight Into Tumour Heterogeneity
… (i), determination of frequency and nature of mutations in KA-ras and (ii), determination of the nature and extent of genetic aberrations, at chromosomal level, in advanced colorectal cancer. The main theme of the work was the use of paired tumour samples from the same patients in an attempt to …
-
Inhibition of RAS as a novel therapeutic approach in Luminal B breast cancer.
Historically, the RAS oncoprotein has not been implicated in breast cancer due to less than 1% of breast cancer cases bearing oncogenic RAS mutations. Recently, however, it has been reported that greater than 60% of Luminal B breast cancer cases have a decreased expression of negative RAS …
-
ELUCIDATING THE FUNCTION OF ISOPRENYLCYSTEINE CARBOXYLMETHYLTRANSFERASE (ICMT) IN CANCER
Isoprenylcysteine carboxylmethyltransferase (Icmt), the enzyme catalyzing the last step of the prenylation pathway for proteins with C-terminal CaaX-motifs such as Ras, has been investigated for its potential to be developed as a target for cancer therapy, especially for mutant Ras-driven cancers. …
-
Αλληλεπίδραση των ογκογονιδίων ras με παπίλλομα-ιούς και ερπητο-ιούς σε γυναικολογικές νεοπλασίες
… alterations. In the present study activation of ras genes was examined in female genital lesions. Breast carcinomas were also included due to the higher prevalence of such tumors in women. Presence of the human papillomavirus (HPV) as well as the herpesviruses CMV, HSV and EBV was also detected …
-
ΔΟΜΙΚΗ ΚΑΙ ΛΕΙΤΟΥΡΓΙΚΗ ΑΝΑΛΥΣΗ ΤΗΣ ΟΙΚΟΓΕΝΕΙΑΣ ΤΩΝ ΟΓΚΟΓΟΝΙΔΙΩΝ RAS
… STRUCTURAL AND FUNCTIONAL MODIFICATIONS OF THE RAS GENES. QUANTITATIVE, COMPETITIVE (RT-)PRC - RFLP ASSAYS WERE DEVELOPED TO DETECT AND DISCRIMINATE THE EXPRESSION OF MUTANT VERSUS WILD - TYPE ALLELES OF THE K - RAS AND H - RAS GENE. ANALYSIS OF COLORECTAL TUMORS ESTABLISHED CODON 12 AND CODON …
-
Expressão da iodotironina desiodase tipo 3 no carcinoma diferenciado de tireóide
… on differentiated thyroid tumorigenesis. Point mutations in BRAF and RAS genes and RET/PTC rearrangements are observed in about 70% of PTC cases. Follicular carcinomas commonly harbor RAS mutations and PAX8-PPARJ rearrangements. Anaplastic carcinomas may harbor a wide set of genetic alterations, …
-
The role of FBXO11 in human hematopoiesis
… sequencing study has revealed frequent somatic mutations in ubiquitin proteasome system (UPS) genes, with recurrent loss-of-function mutations in FBXO11, which codes substrate-recognition component for E3 ubiquitin ligase complex. Our mouse transplant model shows a biological cooperation between …
-
Regulation of expression of the intestinal MUC2 gene in vitro and in vivo
… differences, such as frequency of p53 and Ki-ras mutations suggested that development of mucinous and nonmucinous tumours occurs along two distinct genetic pathways. To clarify the details of these pathways, the mechanism of MUC2 gene expression regulation was investigated. In the present work …
Page 1 of 3